Skip to main content

Advertisement

SpringerLink
Log in

Novel Antifungal Drugs Against Fungal Pathogens: Do They Provide Promising Results for Treatment?

  • Original Article
  • Published:
Indian Journal of Hematology and Blood Transfusion Aims and scope Submit manuscript

Abstract

The febrile neutropenia episodes of hematological patients and their outcomes were evaluated with respect to fungal pathogens and antifungal therapy in this retrospective study. All patients, who were older than 14 years of age and developed at least one neutropenic episode after chemotherapy due to hematological cancer from November 2010 to November 2012, were included into the study. We retrospectively collected demographic, treatment, and survival data of 126 patients with neutropenia and their 282 febrile episodes. The mean Multinational Association for Supportive Care in Cancer score was 17.18 ± 8.27. Systemic antifungal drugs were initiated in 22 patients with 30 culture-proven invasive fungal infections (IFIs), 25 attacks of 19 patients with probable invasive pulmonary aspergillosis (IPA), 42 attacks of 38 patients with possible IPA, and 31 attacks of 30 patients with suspected IFI. Voriconazole (VOR), caspofungin and liposomal amphotericin B were used to treat 72 episodes of 65 patients, 45 episodes of 37 patients and 34 episodes of 32 patients as a first-line therapy, respectively. Unfavorable conditions of our hematology ward are thought to increase the number of cases with invasive pulmonary aspergillosis and VOR use. It should be taken into consideration that increased systemic and per oral VOR usage predisposes patients to colonization and infection with azole-resistant fungal strains. Catheters should be removed in cases where patients’ conditions are convenient to remove it. Acute myeloblastic leukemia cases that are more likely to develop invasive fungal infections should be monitored closely for early diagnosis and timely initiation of antifungal drugs which directly correlates with survival rates.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA et al (2011) Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52:56–93

    Article  Google Scholar 

  2. Ellis M (2008) Febrile neutropenia. Ann N Y Acad Sci 1138:329–350

    Article  PubMed  Google Scholar 

  3. Aisner J, Wiernik PH, Schimpf SC (1977) Treatment of invasive aspergillosis: relation of early diagnosis and treatment to response. Ann Intern Med 86:539–543

    Article  CAS  PubMed  Google Scholar 

  4. De Naurois J, Novitzky-Basso I, Gill MJ, Marti FM, Cullen MH, Roila F (2010) Management of febrile neutropenia: ESMO clinical practice guidelines. Ann Oncol 21:252–256

    Article  Google Scholar 

  5. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D et al (1999) Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 340(10):764–771

    Article  CAS  PubMed  Google Scholar 

  6. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T et al (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730–751

    Article  PubMed  Google Scholar 

  7. Caillot D, Couaillier JF, Bernard A, Casasnovas O, Denning DW, Mannone L et al (2001) Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computerised tomography scans in patients with neutropenia. J Clin Oncol 19(1):253–259

    CAS  PubMed  Google Scholar 

  8. Ascioglu S, Rex HB, De Pauw B, Bennett JE, Bille J, Crokaert F et al (2002) Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34:7–14

    Article  CAS  PubMed  Google Scholar 

  9. Maertens J, Theunissen K, Verbeken E, Lagrou K, Verhaegen J, Boogaerts M, Eldere JV (2004) Prospective clinical evaluation of lower cut-offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients. Br J Haematol 126:852–860

    Article  CAS  PubMed  Google Scholar 

  10. Bates DW, Su L, Yu DT, Chertow GM, Seger DL, Gomes DR et al (2001) Correlates of acute renal failure in patients receiving parenteral amphotericin B. Kidney Int 60(4):1452–1459 (2001)

    Article  CAS  PubMed  Google Scholar 

  11. Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A, L Amph/ABLC Collaborative Study Group (2000) A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis 31(5):1155–1163

    Article  CAS  PubMed  Google Scholar 

  12. Viscoli C, Varnier O, Machetti M (2005) Infections in patients with febrile neutropenia: epidemiology, microbiology, and risk stratification. Clin Infect Dis 40(Suppl 4):240–245

    Article  Google Scholar 

  13. Martino R, Subirà M (2002) Invasive fungal infections in hematology: new trends. Ann Hematol 81:233–243

    Article  CAS  PubMed  Google Scholar 

  14. Montagna MT, Giglio ODG, Napoli C, Lovero G, Caggiano G, Delia M, Pastore D, Santoro N, Specchia G (2012) Invasive fungal infections in patients with hematologic malignancies (aurora project): lights and shadows during 18-months surveillance. Int J Mol Sci 13:774–787

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Ng TB, Cheung RC, Xj Ye, Fang EF, Chan YS, Pan WL, Dan XL et al (2012) Pharmacotherapy approaches to antifungal prophylaxis. Expert Opin Pharmacother 13(12):1695–1705

    Article  CAS  PubMed  Google Scholar 

  16. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA et al (2008) Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46:327–360

    Article  CAS  PubMed  Google Scholar 

  17. Sugar AM (1995) Use of amphotericin B with azole antifungal drugs: what are we doing? Antimicrob Agents Chemother 39:1907–1912

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Denning DW, Hanson LH, Perlman AM, Stevens DA (1992) In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents. Diagn Microbiol Infect Dis 15:21–34

    Article  CAS  PubMed  Google Scholar 

  19. Caillot D, Thiébaut A, Herbrecht R, de Botton S, Pigneux A, Bernard F et al (2007) Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer 110(12):2740–2746

    Article  CAS  PubMed  Google Scholar 

  20. Rojas R, Molina JR, Jarque I, Montes C, Serrano J, Sanz J, Besalduch J et al (2012) Outcome of antifungal combination therapy for invasive mold infections in hematological patients is independent of the chosen combination. Mediterr J Hematol Infect Dis 4(1):e2012011

    Article  PubMed Central  PubMed  Google Scholar 

  21. Auberger J, Lass-Flörl C, Aigner M, Clausen J, Gastl G, Nachbaur D (2012) Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high riskpatients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational study. J Antimicrob Chemother 67(9):2268–2273

    Article  CAS  PubMed  Google Scholar 

  22. Mikulska M, Novelli A, Aversa F, Cesaro S, de Rosa FG, Girmenia C et al (2012) Voriconazole in clinical practice. J Chemother 24(6):311–327

    Article  CAS  PubMed  Google Scholar 

  23. Nivoix Y, Launoy A, Lutun P, Moulin JC, Pang KAP, Fornecker LM et al (2012) Adherence to recommendations for the use of antifungal agents in a tertiary care hospital. J Antimicrob Chemother 67(10):2506–2513

    Article  CAS  PubMed  Google Scholar 

  24. van der Linden JW, Snelders E, Kampinga GA, Rijnders BJ, Mattsson E, Debets-Ossenkopp YJ et al (2011) Clinical implications of azole resistance in Aspergillus fumigatus, the Netherlands, 2007–2009. Emerg Infect Dis 17:1846–1854

    Article  PubMed Central  PubMed  Google Scholar 

  25. De Pauw BE, Donnelly JP (2007) Prophylaxis and aspergillosis—has the principle been proven? N Engl J Med 356(4):409–411

    Article  PubMed  Google Scholar 

  26. Iatta R, Caggiano G, Cuna T, Montagna MT (2011) Antifungal susceptibility testing of a 10-year collection of Candida spp. isolated from patients with candidemia. J Chemother 23(2):92–96

    Article  CAS  PubMed  Google Scholar 

  27. Auberger J, Lass-Flörl C, Ulmer H, Nogler-Semenitz E, Clausen J, Gunsilius E, Einsele H, Gastl G, Nachbaur D (2008) Significant alterations in the epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. Int J Hematol 88(5):508–515

    Article  PubMed  Google Scholar 

  28. Zirkel J, Klinker H, Kuhn A, Abele-Horn M, Tappe D, Turnwald D, Einsele H, Heinz H (2012) Epidemiology of Candida blood stream infections in patients with hematological malignancies or solid tumors. Med Mycol 50(1):50–55

    Article  PubMed  Google Scholar 

  29. Blay JY, Chauvin F, Le Cesne A, Anglaret B, Bouhour D, Lasset C, Freyer G, Philip T, Biron P (1996) Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol 14:636

    CAS  PubMed  Google Scholar 

  30. Miceli MH, Diaz JA, Lee SA (2011) Emerging opportunistic yeast infections. Lancet Infect Dis 11:142–151

    Article  PubMed  Google Scholar 

  31. Morgan J, Meltzer MI, Plikaytis BD, Sofair AN, Huie-White S, Wilcox S et al (2005) Excess mortality, hospital stay, and cost due to candidemia: a case–control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol 26:540–547

    Article  PubMed  Google Scholar 

  32. Nucci M, Anaissie E, Betts RF, Dupont BF, Wu C, Buell DN, Kovanda L, Lortholary O (2010) Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials. Clin Infect Dis 51:295–303

    Article  PubMed  Google Scholar 

  33. Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O’Grady NP et al (2009) Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 49:1–45

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  34. Ullmann AJ, Akova M, Herbrecht R, Viscoli C, Arendrup MC, Arikan-Akdagli S, Bassetti M et al (2012) ESCMID guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect 18(Suppl. 7):53–67

    Article  CAS  PubMed  Google Scholar 

  35. Mokaddas EM, Noura AZ, Khan U (2007) Species distribution and antifungal susceptibility of Candida bloodstream isolates in Kuwait: a 10-year study. J Med Microbiol 56:255–259

    Article  CAS  PubMed  Google Scholar 

  36. Pfaller MA, Messer SA, Boyken L, Tendolkar S, Hollis RJ, Diekema DJ (2004) Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS antifungal surveillance program conducted in 2001 and 2002. J Clin Microbiol 42:3142–3146

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  37. Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA (2004) Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 39:743–746

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Infectious Diseases and Clinical Microbiology, Ministry of Health Okmeydanı Training and Research Hospital, S. B. Okmeydanı Eğitim ve Araştırma Hastanesi Şişli, Istanbul, Turkey

    Habip Gedik, Funda Şimşek, Taner Yıldırmak & Arzu Kantürk

  2. Department of Hematology, Ministry of Health Okmeydanı Training and Research Hospital, S. B. Okmeydanı Eğitim ve Araştırma Hastanesi Şişli, Istanbul, Turkey

    Deniz Arıca, Demet Aydın, Naciye Demirel & Osman Yokuş

Authors
  1. Habip Gedik
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Funda Şimşek
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Taner Yıldırmak
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Arzu Kantürk
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Deniz Arıca
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Demet Aydın
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Naciye Demirel
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Osman Yokuş
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Habip Gedik.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gedik, H., Şimşek, F., Yıldırmak, T. et al. Novel Antifungal Drugs Against Fungal Pathogens: Do They Provide Promising Results for Treatment?. Indian J Hematol Blood Transfus 31, 196–205 (2015). https://doi.org/10.1007/s12288-014-0370-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12288-014-0370-8

Keywords

Search

Navigation